• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 22, 2023 at 10:32: AM
via The PARP inhibitor class is welcoming its second FDA approval in prostate cancer in the span of several weeks. The new approval, for Pfizer, is broader than the first but still limited.

article source
 

<



Similar threads

cafead
ASCO GU: Pfizer touts Talzenna&#039;s strong showing in PARP prostate cancer battle with...
Replies
0
Views
167
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Can Pfizer&#039;s new breast cancer drug Talzenna really make a dent in the PARP field?
Replies
0
Views
278
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vaxcyte&#039;s &#039;stunning&#039; 31-valent pneumococcal vaccine win against Pfizer&#039;s Prevnar 20 has analysts thinking big
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer, BioNTech&#039;s combo mRNA shot is latest to be defeated by influenza strain B
Replies
0
Views
11
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote